Pfizer’s Talzenna cleared for breast cancer
admin 17th October 2018 Uncategorised 0US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.
More: Pfizer’s Talzenna cleared for breast cancer
Source: News